Equity Profile

GRAL

GRAIL, Inc.

Health CareBiotechnology$3.0B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests....

Key Metrics to Watch

EPS

Earnings per share is crucial for understanding the company's profitability and financial health.

$-2.45

Revenue

Revenue figures will indicate the company's sales performance and market demand for its products.

$44M

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests. Operating in the health care sector, GRAIL aims to improve patient outcomes by identifying cancers at earlier stages, which is a significant theme in modern medicine.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In Q1-2026, GRAIL reported an EPS of $-2.29, which was better than analysts' expectations of $-3.00, marking a positive surprise. However, revenue details were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GRAIL to report a loss of $-2.45 per share with revenues around $44 million. The company has consistently surprised on the upside in previous quarters.

Bull Case

If GRAIL continues its trend of beating EPS estimates, it could signal strong demand for its cancer detection tests, potentially boosting investor confidence.

Bear Case

On the downside, if GRAIL fails to meet expectations or provides weak guidance, it may raise concerns about its growth prospects and market position.

Key Metrics to Watch

EPS

$-2.45

Earnings per share is crucial for understanding the company's profitability and financial health.

Revenue

$44M

Revenue figures will indicate the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GRAIL's revenue meet or exceed the $44 million consensus estimate?

Revenue performance is critical for assessing market demand and the effectiveness of GRAIL's products.

How will management address the ongoing losses and future profitability?

Investors will be keen to understand the company's path to profitability and any strategic changes that may be implemented.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GRAIL's ability to leverage its innovative technology for market growth, especially given its history of beating estimates.

Supporting Evidence

GRAIL has consistently surprised on EPS in recent quarters, indicating stronger operational performance than expected.

The options market is pricing in a larger move than historical averages, suggesting that traders anticipate significant news.

Key Risk

If GRAIL's revenue significantly exceeds $44 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether GRAIL can sustain its growth trajectory amidst ongoing losses.

Bull Confirmed If

An EPS of $-2.45 or better, along with revenue exceeding $44 million, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-2.98 and revenue below $42 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move in the stock following the earnings report, suggesting heightened volatility.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests the stock could rise by around 1.90%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a significant decline, with historical patterns suggesting a drop of around 5.31%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships that could drive revenue growth.
2Management's commentary on market demand for cancer detection tests.
3Insights into cost management strategies to improve profitability.
4Details on customer feedback and clinical trial results for existing products.
5Future guidance on revenue expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests....

Key Metrics to Watch

EPS

Earnings per share is crucial for understanding the company's profitability and financial health.

$-2.45

Revenue

Revenue figures will indicate the company's sales performance and market demand for its products.

$44M

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In Q1-2026, GRAIL reported an EPS of $-2.29, which was better than analysts' expectations of $-3.00, marking a positive surprise. However, revenue details were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GRAIL to report a loss of $-2.45 per share with revenues around $44 million. The company has consistently surprised on the upside in previous quarters.

Bull Case

If GRAIL continues its trend of beating EPS estimates, it could signal strong demand for its cancer detection tests, potentially boosting investor confidence.

Bear Case

On the downside, if GRAIL fails to meet expectations or provides weak guidance, it may raise concerns about its growth prospects and market position.

Key Metrics to Watch

EPS

$-2.45

Earnings per share is crucial for understanding the company's profitability and financial health.

Revenue

$44M

Revenue figures will indicate the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GRAIL's revenue meet or exceed the $44 million consensus estimate?

Revenue performance is critical for assessing market demand and the effectiveness of GRAIL's products.

How will management address the ongoing losses and future profitability?

Investors will be keen to understand the company's path to profitability and any strategic changes that may be implemented.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GRAIL's ability to leverage its innovative technology for market growth, especially given its history of beating estimates.

Supporting Evidence

GRAIL has consistently surprised on EPS in recent quarters, indicating stronger operational performance than expected.

The options market is pricing in a larger move than historical averages, suggesting that traders anticipate significant news.

Key Risk

If GRAIL's revenue significantly exceeds $44 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether GRAIL can sustain its growth trajectory amidst ongoing losses.

Bull Confirmed If

An EPS of $-2.45 or better, along with revenue exceeding $44 million, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-2.98 and revenue below $42 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move in the stock following the earnings report, suggesting heightened volatility.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests the stock could rise by around 1.90%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a significant decline, with historical patterns suggesting a drop of around 5.31%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships that could drive revenue growth.
2Management's commentary on market demand for cancer detection tests.
3Insights into cost management strategies to improve profitability.
4Details on customer feedback and clinical trial results for existing products.
5Future guidance on revenue expectations for the next quarter.